Saturday 17 October 2026 Export NVNO’s income statement to Excel — free account

enVVeno Medical Corporation

In the quarter to June 2026, EPS grew 53.6% and free cash flow grew 4.60%, each against the same quarter a year earlier.

7.47 0.46 −5.80%

Follow NVNO

Alert me

Market cap: $5.5M
P/E: 0.0×
Fwd P/E: −0.7×
Dividend yield: —
F-score: 3/9
Altman Z: −28.30
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.00

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	1	—	—	1	—	—	1	—	—	1	—

Insider Ownership 0.15%

Capital & Financial Ratios $m

Market Cap 5.50

Revenue 0.19

Net Income (15.72)

Free Cash Flow (14.62)

Net Debt (21.49)

Current Ratio 11.70

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (0.70)

P/S ratio 27.19

P/B ratio 0.25

Past 5Y EPS Growth —

This Y EPS Growth 14.96%

Next Y EPS Growth 7.41%

Next Y revenue growth (100.00%)

Next 5Y EPS Growth 48.08%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 0.52%

10-year low 10-year high

P/B against its own 10 years 3.07%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	46	43	28	21
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	47	44	29	22

	2023	2024	2025	Q'26
Payables	1	2	2	1
ST’ Debt	—	—	—	—
Other	—	—	—	—
	1	2	2	2

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	(65.89%)
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	30.76%	(11.19%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’19	0	—	—	—	0
’18	0	0	0	0	0
’17	0	0	0	0	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(4)	—	—	—
’25	(4)	(4)	(4)	(3)	(16)
’24	(4)	(4)	(4)	(5)	(17)
’23	(5)	(5)	(4)	(5)	(19)
’22	(3)	(4)	(4)	(4)	(16)
’21	(4)	(3)	(2)	(3)	(12)
’20	(1)	(1)	(3)	(3)	(8)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(4)	—	—	—
’25	(4)	(4)	(4)	(3)	(16)
’24	(4)	(4)	(4)	(5)	(17)
’23	(5)	(5)	(4)	(5)	(19)
’22	(3)	(4)	(4)	(4)	(16)
’21	(4)	(3)	(2)	(3)	(12)
’20	(1)	(1)	(3)	(3)	(8)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(5.89)	(5.37)	—	—	—
’25	(7.72)	(11.58)	(8.07)	(5.89)	(33.06)
’24	(10.88)	(10.88)	(12.28)	(10.53)	(44.56)
’23	(20.00)	(20.35)	(15.79)	(11.23)	(67.02)
’22	(16.49)	(22.10)	(18.95)	(19.30)	(77.08)
’21	(16.84)	(9.82)	(9.13)	(32.98)	(66.67)
’20	(52.63)	(70.17)	(52.63)	(78.70)	(264.56)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	1,164.63	332.50	184.63	174.65	117.25	87.85	85.75	10.54	Analyst estimates 2026–2028 Powerpack
	High	—	—	4,935.00	3,018.75	743.75	398.30	277.55	227.15	243.95	196.70
People
People	Employees	—	12	9	12	19	24	30	31	37	33
	Revenue/emp, $m	0.00	0.04	0.02	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	1	0	0	0	—	—	—	—	—	—
	Gross margin, %	(3.10)	0.59	100.00	100.00	0.00	0.00	0.00	—	—	—
	EBT	(6)	(8)	(13)	(8)	(9)	(17)	(25)	(24)	(22)	(19)
	EBT margin, %	(711.07)	(1,845.89)	(6,989.66)	(24,440.38)	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	(3)	(8)	(13)	(8)	(9)	(17)	(25)	(24)	(22)	(19)
	Depreciation	0	2	7	0	0	0	1	1	1	0
Per share, $
Per share, $	Revenue	113.90	60.30	17.44	1.73	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	(491.89)	(1,115.49)	(1,535.09)	(421.05)	(264.56)	(66.67)	(91.39)	(67.02)	(44.56)	(33.06)
	Cash flow	(495.25)	(600.31)	(594.00)	(327.58)	(208.62)	(47.89)	(48.79)	(53.79)	(34.36)	(26.43)
	Capex	18.13	22.19	(1.16)	(20.22)	(4.90)	(1.49)	(0.36)	(0.09)	(0.08)	(0.01)
	Free cash flow	(477.12)	(578.13)	(595.16)	(347.79)	(213.52)	(49.38)	(49.15)	(53.88)	(34.44)	(26.44)
	Book value	(611.51)	(1,590.07)	190.32	54.99	192.88	219.90	120.99	131.77	86.04	46.06
	Shares, m	0	0	0	0	0	0	0	0	0	1
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	—	—	—	—	—	—
	P/S	110.75	110.75	73.97	46.37	—	—	—	—	—	—
	P/B	0.00	0.00	6.78	8.75	—	—	—	—	—	—
	EV/Sales	125.38	125.38	83.65	63.72	—	—	—	—	—	—
	EV/FCF	(7.17)	(7.17)	(2.45)	(1.90)	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	(3)	(4)	(6)	(6)	(8)	(12)	(16)	(19)	(17)	(16)
	Capex	0	0	0	0	0	0	0	0	0	0
	Free cash flow	(3)	(4)	(6)	(6)	(8)	(12)	(16)	(19)	(17)	(16)
Balance, $m
Balance, $m	Working capital	(1)	(3)	1	0	6	53	38	46	42	27
	Total debt	0	2	—	1	0	2	1	—	—	—
	Net debt	0	2	(3)	(1)	(9)	(55)	(39)	(46)	(43)	(28)
	Shareholders’ equity	(4)	(11)	2	1	7	54	39	46	42	27
Returns, %
Returns, %	ROA	(186.62)	(412.80)	(566.40)	(218.07)	(139.46)	(48.44)	(49.66)	(52.09)	(46.63)	(52.26)
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	48.60	107.51	359.63	(503.94)	(240.92)	(53.75)	(52.98)	(55.38)	(49.39)	(56.21)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2019 · latest quarter Mar 2019

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
WOK WORK Medical Technology Group LTD	$6.0M	—	—	—	—	−948.94% (below 0%: shrinking)	—	—	Compare
AMIX Autonomix Medical, Inc.	$5.7M	— (loss-making)	—	—	n/m	−36.10% (below 0%: shrinking)	—	0.00%	Compare
NVNO enVVeno Medical Corporation	$5.5M	— (loss-making)	— (loss-making)	+0.32% (above 0%: growing)	n/m	+4.60% (above 0%: growing)	0.00%	0.00%
CODX Co-Diagnostics, Inc.	$5.3M	— (loss-making)	— (loss-making)	+1.96% (above 0%: growing)	n/m	+17.47% (above 0%: growing)	72.73%	(3,733.17%)	Compare
TBIO Telesis Bio Inc.	$5.3M	— (loss-making)	— (loss-making)	−61.79% (below 0%: shrinking)	n/m	−17.96% (below 0%: shrinking)	64.43%	(349.74%)	Compare
VNRX VolitionRX Limited	$5.3M	— (loss-making)	— (loss-making)	−1.97% (below 0%: shrinking)	n/m	+18.58% (above 0%: growing)	100.00%	(1,042.39%)	Compare
TRIB Trinity Biotech PLC	$5.1M	— (loss-making)	— (loss-making)	+43.28% (above 0%: growing)	n/m	+75.24% (above 0%: growing)	35.43%	(24.53%)	Compare
VVOS Vivos Therapeutics, Inc.	$4.8M	— (loss-making)	— (loss-making)	+34.90% (above 0%: growing)	n/m	+16.44% (above 0%: growing)	57.31%	(93.63%)	Compare
INBS Intelligent Bio Solutions Inc.	$4.8M	— (loss-making)	5.4×	+51.10% (above 0%: growing)	n/m	−31.59% (below 0%: shrinking)	43.23%	(360.19%)	Compare
Median of peers	$5.3M	—	—	+18.43%	—	−0.76%	60.87%	(349.74%)

All 149 Medical Devices stocks →

enVVeno Medical Corporation (NVNO) key facts

enVVeno Medical Corporation (NVNO) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, NVNO traded at $7.47, a market capitalization of $5.5 million.
Return on equity was −56.2% and debt-to-equity 0.00.

Source: company filings (standardised) and stockrow calculations.